Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their research efforts around the adeno-associated virus (AAV) vectors used ...

For Vertex Pharmaceuticals, the first quarter of 2025 brought good news and bad news. On the bright side, early momentum for newly launched cystic fibrosis (CF) med Alyftrek and pain treatment ...

May 5 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue ...

Vertex Pharmaceuticals misses analyst estimates on the top and bottom lines in the first quarter. Vertex raises its full-year 2025 revenue guidance to a range of $11.85 billion to $12 billion ...

Vertex Pharmaceuticals is expanding its manufacturing capabilities for its gene therapy Casgevy, signaling growing demand for the treatment. Business of Pride Join the Boston Business Journal for ...

In recent years, backyard bird watching has evolved from a quiet pastime into an interactive experience, thanks to the arrival of smart bird feeders. The Happy Birdy Smart Feeder combines high ...

Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic fibrosis, and little or no contributions from a gene ...

Need a break? Play the USA TODAY Daily Crossword Puzzle. More: Rod Stewart receives Lifetime Achievement Award at AMAs, performs 'Forever Young' Here are some of the most memorable moments from ...